Radosevich J A, Gould K A, Koukoulis G K, Haines G K, Rosen S T, Lee I, Gould V E
Department of Medicine, Northwestern University/Veterans Administration Lakeside Medical Center, Chicago, Illinois 60611.
Ultrastruct Pathol. 1993 Jan-Feb;17(1):1-8. doi: 10.3109/01913129309015397.
Fifty-five cases representing a spectrum of disease states of the human liver and 10 normal liver controls were examined for the presence of the ras oncogene product p21. Conventional formalin-fixed, paraffin-embedded sections were immunostained by the avidin-biotin complex method with the broadly reactive ras p21 monoclonal antibody (Mab) RAP-5. The specificity of the reactions was confirmed by immunostaining selected samples with Mab Y13-259. In the normal liver, virtually no hepatocytic immunostaining was noted. Variable, often extensive, and convincing immunoreactions were noted in diverse forms of hepatitis, cirrhosis, and allograft rejection; the strongest immunostaining was found in samples of focal nodular hyperplasia. Hepatic adenomas and hepatocellular carcinomas showed unevenly distributed, moderate to weak reactions or no reaction at all; cholangiocarcinomas did not immunostain. In reactive but non-transformed liver cell populations, enhanced p21 ras reactions seemed to correlate with the severity of the injury and the intensity of the proliferative response. The uneven and comparatively weak ras p21 reactions noted in adenomas and carcinomas suggest that this oncogene product may be involved only transitorily in their transformation processes and possibly may not be involved in certain variants thereof.
对55例代表人类肝脏一系列疾病状态的病例以及10例正常肝脏对照进行了ras癌基因产物p21的检测。采用抗生物素蛋白-生物素复合物法，用具有广泛反应性的ras p21单克隆抗体（Mab）RAP-5对常规福尔马林固定、石蜡包埋的切片进行免疫染色。用Mab Y13-259对选定样本进行免疫染色，证实了反应的特异性。在正常肝脏中，几乎未观察到肝细胞免疫染色。在各种形式的肝炎、肝硬化和同种异体移植排斥反应中，观察到不同程度的、通常广泛且令人信服的免疫反应；在局灶性结节性增生样本中发现最强的免疫染色。肝腺瘤和肝细胞癌显示出分布不均、中度至弱反应或根本无反应；胆管癌未出现免疫染色。在反应性但未转化的肝细胞群体中，增强的p21 ras反应似乎与损伤的严重程度和增殖反应的强度相关。在腺瘤和癌中观察到的ras p21反应不均且相对较弱，表明这种癌基因产物可能仅短暂参与其转化过程，并且可能不参与某些变体的转化过程。
